SCHEMBL2430971

SCHEMBL2430971

N[C@H]1C[C@H]2CC[C@@H](C1)N2c1ccc(C(=O)NCc2ccccc2)cn1

nearest known ligand 0.74

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 7/20 0.74
HSP90AB1 P08238 7/20 0.74
ALDH1A1 P00352 2/20 0.57
RAB9A P51151 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
KDM4E B2RXH2 1/20 0.57
MAPK1 P28482 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.55
HPGDS O60760 4/20 0.51
KDM1A O60341 1/20 0.50
RCOR1 Q9UKL0 1/20 0.50
MAOA P21397 1/20 0.50
NPC1 O15118 1/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
TSHR P16473 1/20 0.48
ALOX15 P16050 1/20 0.47
EGLN1 Q9GZT9 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2430973 1.00 HSP90AA1 (0.74) HSP90AA1HSP90AB1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL3977695 0.87 HSP90AA1 (0.80) HSP90AA1HSP90AB1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL3977699 0.87 HSP90AA1 (0.80) HSP90AA1HSP90AB1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL2429123 0.85 HSP90AA1 (1.00) HSP90AA1HSP90AB1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL2429124 0.85 HSP90AA1 (1.00) HSP90AA1HSP90AB1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL2427598 0.84 HSP90AA1 (0.88) HSP90AA1HSP90AB1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL2427601 0.84 HSP90AA1 (0.88) HSP90AA1HSP90AB1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL2429285 0.83 HSP90AA1 (1.00) HSP90AA1HSP90AB1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL2429288 0.83 HSP90AA1 (1.00) HSP90AA1HSP90AB1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL2430041 0.83 HSP90AA1 (0.63) HSP90AA1HSP90AB1ALDH1A1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8012956-B2 Tropane compounds EXELIXIS, INC. (US) 2011-09-06 US disclosed
EP-2074120-B1 TROPANE COMPOUNDS EXELIXIS INC (US) 2010-03-03 EP disclosed
EP-2074120-A1 TROPANE COMPOUNDS Exelixis, Inc. (US) 2009-07-01 EP disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 US disclosed
WO-2009055077-A1 TROPANE COMPOUNDS EXELIXIS, INC. (US) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163471-A1 Tropane compounds ADRA1B, ADRA2B, ADRB2 HSP90AA1 1888/4885HSP90AB1 1352/4885ALDH1A1 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.